Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
|NCT02166905||II||NY-ESO-1 or LAGE-1+ ovarian cancer with or without residual disease after treatment||A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||View Drugs||New York|
|CDX-1401||DEC-205/NY-ESO-1 fusion protein CDX-1401||Immune response against cancer expressing NY-ESO-1|
|Epacadostat||3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360||Inhibits IDO1 to stimulate immune response|
|NCT02721043||I||Advanced solid tumors||Phase I, Open Label, Study Of Pgv001 A Multi-Peptide Therapeutic Vaccine Platform For Use In The Treatment Of Malignancies In The Adjuvant Setting||View Drugs||New York|
|Lenalidomide||CC-5013, IMID-1, Revlimid||Angiogenesis inhibitor and immunostimulator|
|PGV001||personalized genomic vaccine 001, personalized peptides plus Poly-ICLC vaccine 001||Immune response against tumor-associated antigens|
|poly ICLC||poly-ICLC, Hiltonol, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, poly I:poly C with poly-1-lysine stabilizer||Activates dendritic cells and induces interferon production|